Current molecularly targeting therapies in NSCLC and melanoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 7, 2015, Pages 856-868

  Rajanna, Supriya ^a   Rastogi, Ichwaku ^a   Wojdyla, Luke ^a   Furo, Hiroko ^a   Kulesza, Agnes ^a   Lin, Leo ^a   Sheu, Bonnie ^a   Frakes, Mark ^a   Ivanovich, Marko ^a   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Melanoma; Monoclonal antibodies; NSCLC; Tyrosine kinase inhibitor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AFATINIB; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; AXITINIB; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DACOMITINIB; DASATINIB; ENCORAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MATUZUMAB; NILOTINIB; PANITUMUMAB; SORAFENIB; SUNITINIB; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB; ZALUTUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84938685242     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150202100130     Document Type: Article

References (128)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA. Cancer J. Clin., 2011, 61 (2), 69-90.
2. Urruticoechea, A.; Alemany, R.; Balart, J.; Villanueva, A.; Vinals, F.; Capella, G. Recent advances in cancer therapy: An overview. Curr. Pharm. Des., 2010, 16 (1), 3-10.
3. Riley, L.B.; Desai, D.C. The molecular basis of cancer and the development of targeted therapy. Surg. Clin. North. Am., 2009, 89 (1), 1-15, vii.
4. Fong, J.T.; Jacobs, R.J.; Moravec, D.N.; Uppada, S B.; Botting, G.M.; Nlend, M.; Puri, N. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PloS one, 2013, 8 (11), e78398
5. Etnyre, D.; Stone, A.L.; Fong, J.T.; Jacobs, R.J.; Uppada, S.B.; Botting, G.M.; Rajanna, S.; Moravec, D.N.; Shambannagari, M.R.; Crees, Z.; Girard, J.; Bertram, C.; Puri, N. Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol. Ther., 2014, 15(9), 1129-1141.
6. Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic. Proceed., 2008, 83(5), 584-594.
7. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676), 1497-1500.
8. Stone, A.; Harrington, K.; Frakes, M.; Blank, K.; Rajanna, S.; I., R.; Puri, N. EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer. J. Carcinogen. Mutagenesis, 2014, 5(3).
9. Domvri, K.; Zarogoulidis, P.; Darwiche, K.; Browning, R.F.; Li, Q.; Turner, J.F.; Kioumis, I.; Spyratos, D.; Porpodis, K.; Papaiwannou, A.; Tsiouda, T.; Freitag, L.; Zarogoulidis, K. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J. Cancer, 2013, 4(9), 736-754.
10. Laskin, J. J.; Sandler, A.B. First-line treatment for advanced nonsmall- cell lung cancer. Oncology (Williston Park), 2005, 19(13), 1671-1676 discussion 1678-1680.
11. (a) Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 2007, 12 (6), 713-718
12. Ryan, Q.; Ibrahim, A.; Cohen, M.H.; Johnson, J.; Ko, C.W.; Sridhara, R.; Justice, R.; Pazdur, R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist, 2008, 13(10), 1114-1119
13. Kazandjian, D.; Blumenthal, G.M.; Chen, H.Y.; He, K.; Patel, M.; Justice, R.; Keegan, P.; Pazdur, R. FDA approval summary: Crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist, 2014, 19(10), e5-11
14. Brugger, W.; Thomas, M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment. Lung cancer, 2012, 77(1), 2-8.
15. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Seminars in oncology, 2006, 33(4), 369-385.
16. Dungo, R.T.; Keating, G.M. Afatinib: First global approval. Drugs, 2013, 73(13), 1503-1515.
17. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J.H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; Yokoyama, S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 2002, 110 (6), 775- 787.
18. Klein, P.; Mattoon, D.; Lemmon, M.A.; Schlessinger, J. A structure-based model for ligand binding and dimerization of EGF receptors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101 (4), 929-934.
19. Zhang, Z.; Stiegler, A.L.; Boggon, T.J.; Kobayashi, S.; Halmos, B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1(7), 497-514.
20. Castanon, E.; Martin, P.; Rolfo, C.; Fusco, J.P.; Ceniceros, L.; Legaspi, J.; Santisteban, M.; Gil-Bazo, I. Epidermal growth factor receptor targeting in non-small cell lung cancer: Revisiting different strategies against the same target. Curr. Drug Targ., 2014, 15(14), 1273-1283.
21. Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; Woo, M.S.; Greulich, H.; Wong, K.K.; Meyerson, M.; Eck, M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA, 2008, 105(6), 2070-2075.
22. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; Pazdur, R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist, 2003, 8(4), 303-306.
23. Cohen, M.H.; Johnson, J.R.; Chen, Y.F.; Sridhara, R.; Pazdur, R. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist, 2005, 10(7), 461-466.
24. Engle, J.A.; Kolesar, J.M. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Am. J. Health Syst. Pharm., 2014, 71(22), 1933-1938.
25. (a) Finlay, M.R.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M.R.; Bradbury, R.H.; Brown, S.J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A.; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G.B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H.L.; Mellor, M.J.; Orme, J.P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M.J.; Whittaker, D.; Wells, S.; Wrigley, G. L. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem., 2014, 57(20), 8249-8267
26. Peters, S.; Zimmermann, S.; Adjei, A. A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. Cancer Treat. Rev., 2014, 40(8), 917-26.
27. Psyrri, A.; Seiwert, T.Y.; Jimeno, A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 2013, 246-255
28. Giusti, R.M.; Shastri, K.A.; Cohen, M.H.; Keegan, P.; Pazdur, R. FDA drug approval summary: Panitumumab (Vectibix). Oncologist, 2007, 12 (5), 577-583.
29. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology, 2001, 61 Suppl 2, 1-13
30. Cho, H.S.; Mason, K.; Ramyar, K.X.; Stanley, A.M.; Gabelli, S.B.; Denney, D.W.Jr.; Leahy, D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 2003, 421(6924), 756- 60.
31. Govindan, R. A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. Clin. Lung Cancer, 2010, 11(1), 8-12.
32. Mazieres, J.; Peters, S.; Lepage, B.; Cortot, A. B.; Barlesi, F.; Beau-Faller, M.; Besse, B.; Blons, H.; Mansuet-Lupo, A.; Urban, T.; Moro-Sibilot, D.; Dansin, E.; Chouaid, C.; Wislez, M.; Diebold, J.; Felip, E.; Rouquette, I.; Milia, J. D.; Gautschi, O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol., 2013, 31(16), 1997-2003.
33. Hirsch, F.R.; Varella-Garcia, M.; Cappuzzo, F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene, 2009, 28 Suppl 1, S32-37.
34. Wellstein, A. ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers. Front. Oncol., 2012, 2, 192
35. Souttou, B.; Carvalho, N.B.; Raulais, D.; Vigny, M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J. Biol. Chem., 2001, 276 (12), 9526-9531.
36. Iwahara, T.; Fujimoto, J.; Wen, D.; Cupples, R.; Bucay, N.; Arakawa, T.; Mori, S.; Ratzkin, B.; Yamamoto, T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 1997, 14(4), 439- 449
37. Morris, S.W.; Naeve, C.; Mathew, P.; James, P.L.; Kirstein, M. N.; Cui, X.; Witte, D.P. ALK, the chromosome 2 gene locus altered by the t(2; 5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene, 1997, 14(18), 2175- 2188.
38. Morales La Madrid, A.; Campbell, N.; Smith, S.; Cohn, S.L.; Salgia, R. Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target. Oncol., 2012, 7 (3), 199-210
39. Shaw, A. T.; Solomon, B. Targeting anaplastic lymphoma kinase in lung cancer. Clin. Cancer Res., 2011, 17(8), 2081-2086.
40. Schulte, J.H.; Bachmann, H.S.; Brockmeyer, B.; Depreter, K.; Oberthur, A.; Ackermann, S.; Kahlert, Y.; Pajtler, K.; Theissen, J.; Westermann, F.; Vandesompele, J.; Speleman, F.; Berthold, F.; Eggert, A.; Brors, B.; Hero, B.; Schramm, A.; Fischer, M. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res., 2011, 17(15), 5082-5092
41. Wellstein, A.; Toretsky, J.A. Hunting ALK to feed targeted cancer therapy. Nat. Med., 2011, 17(3), 290-291
42. Proietti, A.; Ali, G.; Pelliccioni, S.; Lupi, C.; Sensi, E.; Boldrini, L.; Servadio, A.; Chella, A.; Ribechini, A.; Cappuzzo, F.; Miccoli, M.; Fontanini, G. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Cancer Cytopathology, 2014, 122(6), 445- 53.
43. Horn, L.; Pao, W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J. Clin. oncolo., 2009, 27 (26), 4232-5
44. Sasaki, T.; Rodig, S.J.; Chirieac, L.R.; Janne, P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer, 2010, 46(10), 1773-1780.
45. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; Ishikawa, Y.; Kimura, H.; Mitsudomi, T.; Tanio, Y.; Mano, H.; Group, A.L.K.L.C.S. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. New Eng. J . Med., 2010, 363 (18), 1734-1739
46. Bang, Y.J. The potential for crizotinib in nonsmall cell lung cancer: A perspective review. Therap. Adv. Med. Oncol., 2011, 3(6), 279-291.
47. Shaw, A.T.; Kim, D.W.; Mehra, R.; Tan, D.S.; Felip, E.; Chow, L.Q.; Camidge, D.R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G.J.; Solomon, B.J.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G.; Santoro, A.; Lau, Y.Y.; Goldwasser, M.; Boral, A.L.; Engelman, J.A. Ceritinib in ALK-rearranged non-small-cell lung cancer. New Engl. J. Med., 2014, 370(13), 1189-1197
48. Awad, M.M.; Shaw, A.T. ALK inhibitors in non-small cell lung cancer: Crizotinib and beyond. Clin. Adv. Hematol. Oncol., , 2014, 12(7), 429-439.
49. Byrne, A.M.; Bouchier-Hayes, D.J.; Harmey, J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med., 2005, 9(4), 777-794
50. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB, 1999, 13(1), 9-22.
51. Olsson, A.K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol., 2006, 7(5), 359-371.
52. Cabebe, E.; Wakelee, H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr. Treat. Opt. Oncol., 2007, 8(1), 15-27.
53. Han, H.; Silverman, J.F.; Santucci, T.S.; Macherey, R.S.; d'Amato, T.A.; Tung, M.Y.; Weyant, R.J.; Landreneau, R.J. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol., 2001, 8(1), 72-79
54. Piperdi, B.; Merla, A.; Perez-Soler, R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs, 2014, 74(4), 403-413.
55. Stewart, D.J. Wnt signaling pathway in non-small cell lung cancer. J. Natl. Cancer Inst., 2014, 106 (1), djt356.
56. Grabowski, P.; Briest, F.; Baum, R.P.; Zaknun, J J.; Kulkarni, H. R.; Zeitz, M.; Horsch, D. Vandetanib therapy in medullary thyroid cancer. Drugs of Today, 2012, 48(11), 723-733.
57. Tang, Y.Q.; Jaganath, I.B.; Manikam, R.; Sekaran, S.D. Inhibition of MAPKs, Myc/Max, NFkappaB, and hypoxia pathways by Phyllanthus prevents proliferation, metastasis and angiogenesis in human melanoma (MeWo) cancer cell line. Int. J. Med. Sci., 2014, 11(6), 564-577.
58. White, R.R.; Stanley, W.E.; Johnson, J.L.; Tyler, D.S.; Seigler, H.F. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann. Surg., 2002, 235(6), 879-887.
59. Costea, C. F.; Anghel, K.; Dimitriu, G.; Dumitrescu, G. F.; Faiyad, Z.; Dumitrescu, A.M.; Sava, A. Anatomoclinical aspects of conjunctival malignant metastatic melanoma. Rom. J. Morphol . Embryol., 2014, 55(3), 933-937.
60. Chong, H.; Vikis, H.G.; Guan, K.L. Mechanisms of regulating the Raf kinase family. Cell. Signalling, 2003, 15(5), 463-439
61. Roskoski, R.Jr. RAF protein-serine/threonine kinases: Structure and regulation. Biochem. Biophys. Res. Commun., 2010, 399(3), 313-317.
62. Hawryluk, E.B.; Tsao, H. Melanoma: Clinical features and genomic insights. Cold Spring Harb. Perspect Med., 2014, 4(9), a015388.
63. Luke, J.J.; Ott, P.A. New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug, Healthc. Patient Saf., 2014, 6, 77-88.
64. Azijli, K.; Stelloo, E.; Peters, G.J.; Van Dan, A.J. New developments in the treatment of metastatic melanoma: Immune checkpoint inhibitors and targeted therapies. Anticancer Res., 2014, 34(4), 1493-1505.
65. Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S.J.; Sosman, J.A.; Kirkwood, J.M.; Eggermont, A.M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K.T.; McArthur, G.A.; Group, B.S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med., 2011, 364(26), 2507-2516.
66. Alcala, A.M.; Flaherty, K.T. BRAF inhibitors for the treatment of metastatic melanoma: Clinical trials and mechanisms of resistance. Clin. Cancer Res., 2012, 18(1), 33-39.
67. Ascierto, P.A.; Minor, D.; Ribas, A.; Lebbe, C.; O'Hagan, A.; Arya, N.; Guckert, M.; Schadendorf, D.; Kefford, R. F.; Grob, J.J.; Hamid, O.; Amaravadi, R.; Simeone, E.; Wilhelm, T.; Kim, K.B.; Long, G.V.; Martin, A.M.; Mazumdar, J.; Goodman, V.L.; Trefzer, U. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol., , 2013, 31(26), 3205-3211.
68. Dhanasekaran, N.; Premkumar Reddy, E. Signaling by dual specificity kinases. Oncogene, 1998, 17 (11), 1447-1455.
69. Gomez, N.; Cohen, P. Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases. Nature, 1991, 353(6340), 170-173.
70. Roskoski, R.Jr. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol. Res., 2012, 66(2), 105-143.
71. Kyriakis, J.M.; App, H.; Zhang, X.F.; Banerjee, P.; Brautigan, D. L.; Rapp, U.R.; Avruch, J. Raf-1 activates MAP kinase-kinase. Nature, 1992, 358(6385), 417-421.
72. Payne, D.M.; Rossomando, A.J.; Martino, P.; Erickson, A.K.; Her, J.H.; Shabanowitz, J.; Hunt, D.F.; Weber, M.J.; Sturgill, T.W. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J., 1991, 10(4), 885-892.
73. Wellbrock, C.; Hurlstone, A. BRAF as therapeutic target in melanoma. Biochem. Pharmacol., 2010, 80(5), 561-567.
74. Ohren, J.F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W.T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D.T.; Leung, I.K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol., 2004, 11(12), 1192-1197.
75. Delaney, A.M.; Printen, J.A.; Chen, H.; Fauman, E.B.; Dudley, D. T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol., 2002, 22(21), 7593-7602.
76. Menzies, A.M.; Long, G.V. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin. Cancer Res., 2014, 20(8), 2035-2043.
77. Kirkwood, J.M.; Bastholt, L.; Robert, C.; Sosman, J.; Larkin, J.; Hersey, P.; Middleton, M.; Cantarini, M.; Zazulina, V.; Kemsley, K.; Dummer, R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res., 2012, 18 (2), 555-567.
78. Robert, C.; Dummer, R.; Gutzmer, R.; Lorigan, P.; Kim, K.B.; Nyakas, M.; Arance, A.; Liszkay, G.; Schadendorf, D.; Cantarini, M.; Spencer, S.; Middleton, M. R. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAFmutant metastatic melanoma: a phase 2 double-blind randomised study. Lance. Oncol., 2013, 14(8), 733-740.
79. Carvajal, R.D.; Sosman, J.A.; Quevedo, J.F.; Milhem, M.M.; Joshua, A.M.; Kudchadkar, R.R.; Linette, G.P.; Gajewski, T.F.; Lutzky, J.; Lawson, D.H.; Lao, C.D.; Flynn, P J.; Albertini, M.R.; Sato, T.; Lewis, K.; Doyle, A.; Ancell, K.; Panageas, K.S.; Bluth, M.; Hedvat, C.; Erinjeri, J.; Ambrosini, G.; Marr, B.; Abramson, D. H.; Dickson, M.A.; Wolchok, J.D.; Chapman, P.B.; Schwartz, G. K. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial. JAMA, 2014, 311(23), 2397-2405.
80. Ascierto, P.A.; Schadendorf, D.; Berking, C.; Agarwala, S.S.; Van Herpen, C.M.; Queirolo, P.; Blank, C.U.; Hauschild, A.; Beck, J. T.; St-Pierre, A.; Niazi, F.; Wandel, S.; Peters, M.; Zubel, A.; Dummer, R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol., 2013, 14(3), 249-256.
81. Rebecca, V.W.; Alicea, G.M.; Paraiso, K.H.; Lawrence, H.; Gibney, G.T.; Smalley, K.S. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pig. Cell Mel. Res., 2014, 27(6), 1154-1158.
82. Lito, P.; Saborowski, A.; Yue, J.; Solomon, M.; Joseph, E.; Gadal, S.; Saborowski, M.; Kastenhuber, E.; Fellmann, C.; Ohara, K.; Morikami, K.; Miura, T.; Lukacs, C.; Ishii, N.; Lowe, S.; Rosen, N. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 2014, 25(5), 697-710.
83. Desch, A.; Strozyk, E.A.; Bauer, A.T.; Huck, V.; Niemeyer, V.; Wieland, T.; Schneider, S.W. Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin alphavbeta5-induced secretion of VEGF-A. Am. J. Pathol., 2012, 181(2), 693-705.
84. Borsig, L. The role of platelet activation in tumor metastasis. Exp. Rev. Anticancer Ther., 2008, 8 (8), 1247-1255.
85. Borsig, L.; Wong, R.; Hynes, R.O.; Varki, N.M.; Varki, A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Nat. Acad. Sci. USA, 2002, 99 (4), 2193-2198.
86. Strizzi, L.; Catalano, A.; Vianale, G.; Orecchia, S.; Casalini, A.; Tassi, G.; Puntoni, R.; Mutti, L.; Procopio, A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol., 2001, 193(4), 468-475.
87. Peppicelli, S.; Bianchini, F.; Calorini, L. Inflammatory cytokines induce vascular endothelial growth factor-C expression in melanoma-associated macrophages and stimulate melanoma lymph node metastasis. Oncol. Lett., 2014, 8(3), 1133-1138.
88. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res., 2006, 66(24), 11851-11858.
89. Eisen, T.; Ahmad, T.; Flaherty, K.T.; Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L.M.; Nathanson, K.L.; Xia, C.; Simantov, R.; Schwartz, B.; Poulin- Costello, M.; O'Dwyer, P.J.; Ratain, M.J. Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis. Bri. J. Cancer, 2006, 95(5), 581-586.
90. Flaherty, K.T.; Lee, S.J.; Zhao, F.; Schuchter, L.M.; Flaherty, L.; Kefford, R.; Atkins, M. B.; Leming, P.; Kirkwood, J.M. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J. Clin. Oncol., 2013, 31 (3), 373-379.
91. Escudier, B.; Gore, M. Axitinib for the management of metastatic renal cell carcinoma. Drugs in R&D, 2011, 11(2), 113-26.
92. Zhang, X.; Fang, X.; Gao, Z.; Chen, W.; Tao, F.; Cai, P.; Yuan, H.; Shu, Y.; Xu, Q.; Sun, Y.; Gu, Y. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs, 2014, 25(2), 204-211.
93. Adamcic, U.; Skowronski, K.; Peters, C.; Morrison, J.; Coomber, B. L. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia, 2012, 14(7), 612-623.
94. Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Peyton, J.D.; Thompson, D.S.; Lane, C.M.; Clark, B.L.; Rubin, M S.; Trent, D. F.; Burris, H.A. 3rd, Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer, 2010, 116(17), 4122-4129.
95. Kwong, L.N.; Davies, M.A. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin. Cancer Res., 2013, 19(19), 5310-5319.
96. Phin, S.; Moore, M.W.; Cotter, P.D. Genomic Rearrangements of PTEN in Prostate Cancer. Front. Oncol., 2013, 3, 240.
97. Babchia, N.; Calipel, A.; Mouriaux, F.; Faussat, A. M.; Mascarelli, F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: Interaction with B-Raf/ERK. Invest. Ophthalmol. Visual Sci., 2010, 51(1), 421-429.
98. Zhu, C.; Qi, X.; Chen, Y.; Sun, B.; Dai, Y.; Gu, Y. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J.Cancer Res., 2011, 137 (11), 1587-1594.
99. Pauls, S.D.; Lafarge, S.T.; Landego, I.; Zhang, T.; Marshall, A.J. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front. Immunol., 2012, 3, 224.
100. Hu, L.; Zaloudek, C.; Mills, G.B.; Gray, J.; Jaffe, R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res., 2000, 6(3), 880- 886.
101. Yarden, Y.; Kuang, W.J.; Yang-Feng, T.; Coussens, L.; Munemitsu, S.; Dull, T.J.; Chen, E.; Schlessinger, J.; Francke, U.; Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987, 6 (11), 3341-3351.
102. Mol, C.D.; Lim, K.B.; Sridhar, V.; Zou, H.; Chien, E.Y.; Sang, B. C.; Nowakowski, J.; Kassel, D.B.; Cronin, C.N.; McRee, D.E. Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem., 2003, 278(34), 31461-31464.
103. Roskoski, R.Jr. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem. Biophys. Res. Communi, 2005, 337 (1), 1-13.
104. Yoshida, H.; Kunisada, T.; Grimm, T.; Nishimura, E. K.; Nishioka, E.; Nishikawa, S. I. Review: Melanocyte migration and survival controlled by SCF/c-kit expression. J. Investig. Dermatol. Symp. Proc., 2001, 6(1), 1-5.
105. (a) Curtin, J. A.; Busam, K.; Pinkel, D.; Bastian, B. C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol., 2006, 24(26), 4340-4346
106. Curtin, J.A.; Fridlyand, J.; Kageshita, T.; Patel, H.N.; Busam, K.J.; Kutzner, H.; Cho, K.H.; Aiba, S.; Brocker, E.B.; LeBoit, P.E.; Pinkel, D.; Bastian, B.C. Distinct sets of genetic alterations in melanoma. New Engl. J. Med., 2005, 353 (20), 2135-2147
107. Carvajal, R.D.; Antonescu, C.R.; Wolchok, J. D.; Chapman, P.B.; Roman, R.A.; Teitcher, J.; Panageas, K.S.; Busam, K.J.; Chmielowski, B.; Lutzky, J.; Pavlick, A.C.; Fusco, A.; Cane, L.; Takebe, N.; Vemula, S.; Bouvier, N.; Bastian, B.C.; Schwartz, G.K. KIT as a therapeutic target in metastatic melanoma. JAMA, 2011, 305(22), 2327-2334.
108. Todd, J.R.; Scurr, L.L.; Becker, T.M.; Kefford, R.F.; Rizos, H. The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene, 2014, 33(2), 236-245.
109. Peng, B.; Dutreix, C.; Mehring, G.; Hayes, M.J.; Ben-Am, M.; Seiberling, M.; Pokorny, R.; Capdeville, R.; Lloyd, P. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J. Clin. Pharmacol., 2004, 44(2), 158-162.
110. Peng, B.; Lloyd, P.; Schran, H. Clinical pharmacokinetics of imatinib. Clini. Pharmacokinet., 2005, 44(9), 879-894.
111. (a) Hodi, F.S.; Corless, C.L.; Giobbie-Hurder, A.; Fletcher, J.A.; Zhu, M.; Marino-Enriquez, A.; Friedlander, P.; Gonzalez, R.; Weber, J.S.; Gajewski, T.F.; O'Day, S.J.; Kim, K.B.; Lawrence, D.; Flaherty, K.T.; Luke, J.J.; Collichio, F.A.; Ernstoff, M.S.; Heinrich, M.C.; Beadling, C.; Zukotynski, K.A.; Yap, J.T.; Van den Abbeele, A.D.; Demetri, G.D.; Fisher, D.E. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol., 2013, 31(26), 3182-3190
112. Carvajal, R.D. Another option in our KIT of effective therapies for advanced melanoma. J. Clin. Oncol., 2013, 31 (26), 3173-3175.
113. Guo, J.; Si, L.; Kong, Y.; Flaherty, K.T.; Xu, X.; Zhu, Y.; Corless, C.L.; Li, L.; Li, H.; Sheng, X.; Cui, C.; Chi, Z.; Li, S.; Han, M.; Mao, L.; Lin, X.; Du, N.; Zhang, X.; Li, J.; Wang, B.; Qin, S. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol., 2011, 29(21), 2904-2909.
114. Minor, D.R.; Kashani-Sabet, M.; Garrido, M.; O'Day, S. J.; Hamid, O.; Bastian, B.C. Sunitinib therapy for melanoma patients with KIT mutations. J. Clin. Oncol.,2012, 18(5), 1457-1463.
115. Cho, J.H.; Kim, K.M.; Kwon, M.; Kim, J.H.; Lee, J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Investig. New Drugs, 2012, 30(5), 2008-2014.
116. Mol, C.D.; Dougan, D.R.; Schneider, T.R.; Skene, R.J.; Kraus, M. L.; Scheibe, D.N.; Snell, G.P.; Zou, H.; Sang, B.C.; Wilson, K.P. Structural basis for the autoinhibition and STI-571 inhibition of c- Kit tyrosine kinase. J. Biol. Chem., 2004, 279(30), 31655-31663.
117. Si, L.; Xu, X.; Kong, Y.; Flaherty, K. T.; Chi, Z.; Cui, C.; Sheng, X.; Li, S.; Dai, J.; Yu, W.; Guo, J. Major response to everolimus in melanoma with acquired imatinib resistance. J. Clin. Oncol., 2012, 30 (4), e37-40.
118. Shimizu, T.; Tolcher, A.W.; Papadopoulos, K.P.; Beeram, M.; Rasco, D.W.; Smith, L.S.; Gunn, S.; Smetzer, L.; Mays, T.A.; Kaiser, B.; Wick, M.J.; Alvarez, C.; Cavazos, A.; Mangold, G.L.; Patnaik, A. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res., 2012, 18(8), 2316-2325.
119. Olson, M.F.; Marais, R. Ras protein signalling. Semin. Immuno., 2000, 12(1), 63-73.
120. Goodsell, D.S. The molecular perspective: The ras oncogene. Stem Cells, 1999, 17(4), 235-236.
121. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 2003, 3(1), 11-22.
122. Denoyelle, C.; Abou-Rjaily, G.; Bezrookove, V.; Verhaegen, M.; Johnson, T.M.; Fullen, D.R.; Pointer, J.N.; Gruber, S.B.; Su, L.D.; Nikiforov, M.A.; Kaufman, R.J.; Bastian, B.C.; Soengas, M.S. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Bio., 2006, 8 (10), 1053-1063.
123. Chin, L.; Tam, A.; Pomerantz, J.; Wong, M.; Holash, J.; Bardeesy, N.; Shen, Q.; O'Hagan, R.; Pantginis, J.; Zhou, H.; Horner, J.W. 2nd; Cordon-Cardo, C.; Yancopoulos, G.D.; DePinho, R.A. Essential role for oncogenic Ras in tumour maintenance. Nature, 1999, 400(6743), 468-472.
124. Shirasawa, S.; Furuse, M.; Yokoyama, N.; Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Kiras. Science, 1993, 260(5104), 85-88.
125. Lim, K.H.; Baines, A.T.; Fiordalisi, J.J.; Shipitsin, M.; Feig, L.A.; Cox, A.D.; Der, C.J.; Counter, C.M. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer cell, 2005, 7 (6), 533-545.
126. Baines, A.T.; Xu, D.; Der, C.J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem., 2011, 3(14), 1787-1808.
127. Martinelli, E.; Troiani, T.; D'Aiuto, E.; Morgillo, F.; Vitagliano, D.; Capasso, A.; Costantino, S.; Ciuffreda, L.P.; Merolla, F.; Vecchione, L.; De Vriendt, V.; Tejpar, S.; Nappi, A.; Sforza, V.; Martini, G.; Berrino, L.; De Palma, R.; Ciardiello, F. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int. J. Cancer, 2013, 13 (9), 2089-2101.
128. Eggermont, A.M.; Kirkwood, J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur. J. Cancer, 2004, 40(12), 1825-1836.